Cure My Disease

Don't miss your cure!

 Log in / Sign up

Green tea, B12, and folic acid: a new weapon against HPV?

NCT ID NCT06285357

Recruiting now Prevention Sponsor: Lo.Li.Pharma s.r.l Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study is testing whether a daily supplement containing green tea extract (EGCG), folic acid, and vitamin B12 can help women clear a persistent high-risk HPV infection in the cervix. About 100 women with a positive HPV test but no serious cell changes will take the supplement for several months. The goal is to see if the supplement increases the chance of the body clearing the virus naturally.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
EGCG (green tea extract), folic acid, and vitamin B12
What this could lead to
If it works, this could point toward a simple, non-invasive way to help the body clear high-risk HPV infections and reduce the risk of cervical cancer.
What could go wrong
This is a very early pilot study with only 100 participants, so results may not be conclusive. Dietary supplements are not a proven treatment for HPV, and the effect may be small or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HPV INFECTION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Azienda Ospedaliero-Universitaria di Modena

    RECRUITING

    Modena, Modena, 41124, Italy

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.